Xipamide
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 584136

CAS#: 14293-44-8

Description: Xipamide is a sulfamoylbenzamide analog of Clopamide. It is a diuretic as well as a saluretic with antihypertensive activity. It is bound to plasma proteins, thus has a delayed onset and prolonged action.

Chemical Structure

img
Xipamide
CAS# 14293-44-8
Instruction

Theoretical Analysis

MedKoo Cat#: 584136
Name: Xipamide
CAS#: 14293-44-8
Chemical Formula: C15H15ClN2O4S
Exact Mass: 354.04
Molecular Weight: 354.800
Elemental Analysis: C, 50.78; H, 4.26; Cl, 9.99; N, 7.90; O, 18.04; S, 9.04

Price and Availability

Size Price Availability Quantity
50mg USD 250 2 weeks
100mg USD 450 2 weeks
250mg USD 850 2 weeks
Bulk inquiry

Synonym: Xipamide; Aquaphor; Zipix; Be 1293; Be-1293; Be1293

IUPAC/Chemical Name: 2',6'-Salicyloxylidide, 4-chloro-5-sulfamoyl-

InChi Key: MTZBBNMLMNBNJL-UHFFFAOYSA-N

InChi Code: InChI=1S/C15H15ClN2O4S/c1-8-4-3-5-9(2)14(8)18-15(20)10-6-13(23(17,21)22)11(16)7-12(10)19/h3-7,19H,1-2H3,(H,18,20)(H2,17,21,22)

SMILES Code: OC1=CC(Cl)=C(S(=O)(N)=O)C=C1C(NC2=C(C)C=CC=C2C)=O

Appearance: Solid powder

Purity: >97% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 354.80 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Tolba MM, Belal F. Two liquid chromatographic approaches for the simultaneous determination of xipamide and its degradation product (2,6-xylidine) using time-programmed fluorescence detection. Luminescence. 2017 Jun;32(4):491-501. doi: 10.1002/bio.3203. Epub 2016 Aug 26. PubMed PMID: 27562288.

2: Abd El-Hay SS, Hashem H, Gouda AA. High performance liquid chromatography for simultaneous determination of xipamide, triamterene and hydrochlorothiazide in bulk drug samples and dosage forms. Acta Pharm. 2016 Mar;66(1):109-18. doi: 10.1515/acph-2016-0022. PubMed PMID: 26959547.

3: Walash MI, El-Enany N, Eid MI, Fathy ME. Stability-Indicating Spectrofluorimetric Methods for the Determination of Metolazone and Xipamide in Their Tablets. Application to Content Uniformity Testing. J Fluoresc. 2014 Mar;24(2):363-76. doi: 10.1007/s10895-013-1301-z. Epub 2013 Oct 4. PubMed PMID: 24091803.

4: Maher HM, Youssef RM, El-Kimary EI, Hassan EM, Barary MA. Bioavailability study of triamterene and xipamide using urinary pharmacokinetic data following single oral dose of each drug or their combination. J Pharm Biomed Anal. 2012 Mar 5;61:78-85. doi: 10.1016/j.jpba.2011.11.032. Epub 2011 Dec 6. PubMed PMID: 22197154.

5: Wagieh NE, Abbas SS, Abdelkawy M, Abdelrahman MM. Spectrophotometric and spectrodensitometric determination of triamterene and xipamide in pure form and in pharmaceutical formulation. Drug Test Anal. 2010 Mar;2(3):113-21. doi: 10.1002/dta.92. PubMed PMID: 20878892.

6: Knauf H, Mutschler E. [Mechanism of action of xipamide and its classification as a "low ceiling diuretic". Pharmacodynamic-pharmacokinetic studies in healthy volunteers and in kidney and liver patients]. Arzneimittelforschung. 2005;55(1):1-14. German. PubMed PMID: 15727159.

7: Balogh A, Merkel U, Müller D. Can xipamide or tacrolimus inhibit the glucuronidation of mycophenolic acid in rat liver slices? Exp Toxicol Pathol. 2003 Jun;54(5-6):375-9. PubMed PMID: 12877348.

8: Taouil K, Féray JC, Brunet J, Christen MO, Garay RP, Hannaert P. Inhibition by xipamide of amiloride-induced acidification in cultured rat cardiocytes. Eur J Pharmacol. 1997 Apr 18;324(2-3):289-94. PubMed PMID: 9145785.

9: Lijnen P, Fagard R, Staessen J, Amery A. Hormonal effects of the diuretic xipamide in healthy men. Cardiovasc Drugs Ther. 1991 Aug;5(4):741-6. PubMed PMID: 1832291.

10: Knauf H, Gerok W, Mutschler E, Schölmerich J, Spahn H, Wietholtz H. Xipamide disposition in liver cirrhosis. Clin Pharmacol Ther. 1990 Dec;48(6):628-32. PubMed PMID: 2249374.

11: Hannaert P, Christen MO, Wierzbicki N, Garay R. [Beneficial effects of xipamide on pH and Ca2+ ions of cardiac cells]. Arch Mal Coeur Vaiss. 1990 Jul;83(8):1271-4. French. PubMed PMID: 2124467.

12: Schauder S. [Photosensitivity following enoxacin and xipamide: combined phototoxic and photo-allergic reaction to enoxacin, photo-allergic reaction to xipamide with subsequent transient light reaction]. Z Hautkr. 1990 Mar;65(3):253-62. German. PubMed PMID: 2140222.

13: Owens CW, Tomlinson B, Liu JB, Graham BR, Gillham C, Smith CC, Betteridge DJ, Prichard BN. A log-dose-response study of xipamide and its effect on metabolic parameters. J Hypertens Suppl. 1989 Dec;7(6):S320-1. PubMed PMID: 2632732.

14: Lijnen P, Amery A. Erythrocyte sodium and potassium transport systems during longterm administration of the diuretic xipamide in men. Methods Find Exp Clin Pharmacol. 1989 Sep;11(9):587-94. PubMed PMID: 2586204.

15: Lijnen P, Hespel P, Fagard R, Staessen J, Goossens W, Lissens W, Amery A. Plasma atrial natriuretic peptide and the renin-aldosterone system during long-term administration of the diuretic xipamide in man. Eur J Clin Pharmacol. 1989;36(2):111-7. PubMed PMID: 2524386.

16: Lijnen P, Fagard R, Staessen J, Amery A. In vitro effect of xipamide on sodium-potassium transport systems in human erythrocytes. Methods Find Exp Clin Pharmacol. 1988 Aug;10(8):527-30. PubMed PMID: 3226221.

17: Nazaret C, Diez J, Hannaert PA, Christen MO, Wierzbicki N, Garay RP. Inhibition of the Cl-/NaCO3- anion exchanger by xipamide in human red blood cells. Eur J Pharmacol. 1987 Dec 15;144(3):353-62. PubMed PMID: 3440481.

18: Prichard BN, Brogden RN. Xipamide. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs. 1985 Oct;30(4):313-32. Review. PubMed PMID: 3905333.

19: Dean S, Kendall MJ, Potter S, Thompson MH, Jackson DA. Nadolol in combination with indapamide and xipamide in resistant hypertensives. Eur J Clin Pharmacol. 1985;28(1):29-33. PubMed PMID: 3987783.

20: Ramsay LE, Freestone S. Xipamide: no advantage over bendrofluazide in hypertension. Br J Clin Pharmacol. 1984 Oct;18(4):616-8. PubMed PMID: 6487502; PubMed Central PMCID: PMC1463626.